论文部分内容阅读
为探讨P53、P16、Bc1－2和Bax蛋白在前列腺癌中的表达和其与病理学分级、临床分期及预后的关系，作者采用免疫组化SP法对51例前列腺癌中上述四种蛋白的表达进行了检测。结果显示：P53、P16、Bc1-2和Bax蛋白在前列腺癌的阳性表达率分别为31．37％、54．90％、21．57％和74．51％；P53和Bc1-2蛋白的表达与前列腺癌的病理学分级和临床分期呈正相关（P＜0.05），而P16和Bax蛋白的表达与前列腺癌的病理分级和临床分期呈负相关（P＜0．05）。P53蛋白的表达还与患者的生存率相关。P53与Bc1－2，以及Bc1－2与Bax表达之间也存在相关性（P＝0．05）。由此提示，检测P53、P16、Bc1-2和Bax四种蛋白的表达，将有助于对前列腺癌患者病理学分级、临床分期和预后的判断。
To investigate the expression of P53, P16, Bc1-2 and Bax in prostatic cancer and its relationship with pathological grade, clinical stage and prognosis, the authors used immunohistochemical SP method to detect the expression of these four proteins in 51 cases of prostate cancer Expression was tested. The results showed that the positive rates of P53, P16, Bc1-2 and Bax in prostate cancer were 31.37%, 54.90%, 21.57% and 74.51%, respectively. The expressions of P53 and Bcl-2 (P <0.05). However, the expression of P16 and Bax was negatively correlated with the pathological grade and clinical stage of prostate cancer (P <0.05). P53 protein expression is also associated with patient survival. There was also a correlation between P53 and Bc1-2, as well as Bc1-2 and Bax expression (P = 0.05). This suggests that the detection of P53, P16, Bc1-2 and Bax four protein expression, will contribute to the pathological grading of prostate cancer patients, clinical stage and prognosis.